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Background: By integrating extracellular signals with actin cytoskeletal changes, Cdc42 plays important roles in cell phys-
iology and has been implicated in human diseases.
Results: A small molecule was found to selectively inhibit Cdc42 in biochemical and cellular assays.
Conclusion: The identified compound is a highly Cdc42-selective inhibitor.
Significance: The described first-in-class Cdc42 GTPase-selective inhibitor will have applications in drug discovery and fun-
damental research.
Cdc42plays important roles in cytoskeletonorganization, cell
cycle progression, signal transduction, and vesicle trafficking.
Overactive Cdc42 has been implicated in the pathology of can-
cers, immune diseases, and neuronal disorders. Therefore,
Cdc42 inhibitors would be useful in probing molecular path-
ways and could have therapeutic potential. Previous inhibi-
tors have lacked selectivity and trended toward toxicity. We
report here the characterization of a Cdc42-selective guanine
nucleotide binding lead inhibitor that was identified by high
throughput screening. A second active analog was identified via
structure-activity relationship studies. The compounds demon-
strated excellent selectivity with no inhibition toward Rho and
Rac in the same GTPase family. Biochemical characterization
showed that the compounds act as noncompetitive allosteric
inhibitors. When tested in cellular assays, the lead compound
inhibited Cdc42-related filopodia formation and cell migration.
The lead compound was also used to clarify the involvement of
Cdc42 in the SinNombre virus internalization and the signaling
pathway of integrin VLA-4. Together, these data present the
characterization of a novel Cdc42-selective allosteric inhibitor
and a related analog, the use of which will facilitate drug devel-
opment targeting Cdc42-related diseases and molecular path-
way studies that involve GTPases.
The Ras-related GTPase superfamily contains 150 mem-
bers of small monomeric guanine nucleotide binding proteins.
This superfamily is further divided into subfamilies based on
sequence as well as functional similarities. Cdc42 is a member
of the RhoGTPase subfamily andwas first identified in Saccha-
romyces cerevisiae as a mediator of cell division (1). Since then,
Cdc42 has been found to be well conserved in organisms rang-
ing from yeast to mammals (2). As a GTPase, Cdc42 functions
in a binary mode with the GTP-bound state active and the
GDP-bound state inactive. Three classes of proteins regulate
the activity status of Cdc42. Guanine nucleotide exchange fac-
tors (GEFs)4 facilitate GDP dissociation and GTP binding and
thus convert Cdc42 to the active state; GTPase-activating pro-
teins catalyze the hydrolysis of boundGTP and returnCdc42 to
the inactive state (3); and guanine nucleotide dissociation
inhibitors (GDIs) sequester Cdc42 in the inactive GDP-bound
state (4). The GTP-bound Cdc42 can interact with multiple
downstream effectors and activate a range of molecular path-
ways. For its functions in cytoskeleton organization, the GTP-
bound Cdc42 binds and activates the kinase p21-activated pro-
tein kinase, which then phosphorylates and activates LIM
kinase, a zinc finger domain-containing protein. This initiates
actin polymerization, which is important for establishing adhe-
rens junctions, invasion, and migration (5). The activated p21-
activated protein kinase is also known to phosphorylate Raf1
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and MEK to enhance the signal through ERK and thus help to
define the transcription profiles of multiple downstream genes
(6). The aberrant activation of these genes frequently leads to
oncogenic transformation. For its role in vesicle trafficking,
Cdc42 has been shown to recruit the Par complex to the apical
membrane to facilitate the exocytosis of vesicles that contain
the apical markers (7). It also acts in combination with various
factors such as PI3K, neuronalWiskott-Aldrich syndrome pro-
tein (N-WASP), and transducer of Cdc42-dependent actin
assembly Toca-1) to regulate membrane tubulation in endocy-
tosis (8).
Considering its diverse functions, it is not surprising that
malfunctions of Cdc42, its upstream regulators, and it down-
stream effectors have been associated with many diseases.
Higher expression levels of Cdc42 are known to correlate with
increased testicular cancer progression and poorer outcome
(9). Overexpression of Cdc42 has also been found in lung can-
cer and cutaneousmelanoma andmay serve as a diseasemarker
and prognosis parameter (10–12).Moreover, the Cdc42 down-
stream effector Par was shown to be expressed at high levels in
prostate cancer and radiation-treated medulloblastoma (13).
BetaPix, a Cdc42GEF, is overexpressed in human breast cancer
(14), whereas in ovarian cancer, the activity of Cdc42was found
to be amplified by upstream signal transducers (15–17). There-
fore, inhibiting Cdc42 could be a useful approach in both cell
biology studies and disease treatment.
The currently available inhibitors of Cdc42 include Clostrid-
ium difficile toxin B (18) and secramine (19), both of which are
limited in their uses. C. difficile toxin B inhibits Cdc42 by add-
ing a glucose moiety to a serine residue through post-transla-
tional modification, blocking the association of Cdc42 with
membranes and preventing downstream signal transduction.
This mechanism of action is similar to some Ras GTPase inhib-
itors, which also act by impeding the interaction of Ras and the
plasmamembrane (20). As for secramine, it stabilizes the inter-
action of Cdc42 and RhoGDI1 and thus locks Cdc42 in an inac-
tive state. In terms of selectivity of these agents,C. difficile toxin
B modifies not only Cdc42 but also Rho and Rac, whereas the
RhoGDIs that can be sequestered by secramine are also regula-
tors for Rho and Rac. Restricting RhoGDIs in a complex with
Cdc42 by secramine could affect the activation status of Rho
andRac. Therefore, these inhibitors lack specificity and as such,
may induce off-target-associated toxicity and possess limited
utility in selective interrogation of Cdc42 involvement in com-
plex cellular pathways. The compound we report here was
identified by high throughput screening of the Molecular
Libraries Small Molecule Repository (21–23). From about
200,000 compounds, 398 were found to decrease fluorescent
GTP binding to one or more GTPases at 10 M. Among them,
CID29950007was chosen for its novel selectivity profile. To the
best of our knowledge, the compound is the first Cdc42 nucle-
otide binding inhibitor ever reported (23). Here it is character-
ized bothmechanistically and in cellular assays to show its util-
ity as a molecular probe.
EXPERIMENTAL PROCEDURES
Materials—GST-taggedGTPaseswere either fromCytoskel-
eton or purified as described previously (24). Cyto-PlexTM
microspheres (4.0 m) were from Thermo Fisher Scientific.
BODIPY FL GTP and BODIPY FL GDP were from Life
Technologies. LDV (4-((N-2-methylphenyl)ureido)-phenyla-
cetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-
L-lysine) and its FITC-conjugated analog (LDV-FITC) were
synthesized by Commonwealth Biotechnology as described
previously (25).N-Formyl-Met-Leu-Phe-Phe (fMLFF)was pur-
chased from Sigma-Aldrich. MTS was from Promega, and
phenazine methosulfate was from Pierce. DAPI and Boyden
chambers were from Thermo Scientific. Reagents were other-
wise from Sigma-Aldrich if not specified. Swiss 3T3 cells and
Vero E6 cells were from ATCC. OVCA429 and SKOV3ip cells
were acquired through a material transfer agreement with MD
Anderson Cancer Center. OVCA429 cells were cultured in Ea-
gle’s minimal essential medium (26), and SKOV3ip cells were
cultured in RPMI 1640 medium (26). The cell cultures were
passaged according to the provided protocols. Sin Nombre vi-
rus strain S77734 was propagated according to the protocol
approved by the biosafety committee of the University of
New Mexico (Public Health Service Registration Number
C20041018-0267). The HyperCyt delivery system and the
CyAnTMADP flow instrumentwere from IntelliCyt andBeck-
man Coulter, respectively.
Synthetic Preparation, Purification, and Analytical Charac-
terization of CID2950007 and CID-44216842—Experimental
details are given in the supplemental data.
Dose-response Inhibition by CID2950007 and Its Analog
CID44216842—The assaywas carried out according to our pre-
viously described protocols (21, 23). Briefly, each individual
GST-tagged enzyme was incubated with glutathione-coated
microsphere beads overnight with gentle rotation. The micro-
sphere beads were labeled with a red fluorescent dye at varying
intensities and therefore could be separated by a flow cytome-
ter. The unbound GTPases were removed by sufficient
washing. The bead sets were then combined. Compound
CID2950007 or CID44216842 at different concentrations and
BODIPY FLGTPwere then added. Final concentrations of the
compounds ranged from 100 M to 15 nM. The mixtures were
incubated at 4 °C for 2 h with gentle rotation. The beads were
sipped and delivered with the HyperCyt instrument and read
on a CyAnTM ADP flow cytometer. Forward scatter and side
scatter were used to define the whole bead population. FL9
channel (excitation/emission: 635/750LP nm) was used to sep-
arate different bead sets. FL1 channel (excitation/emission:
488/530 nm) measures the FITC fluorescence associated with
the beads. As a separate control, GST-tagged GFP was bound
to a set of glutathione beads to which CID2950007 or
CID44216842 was added to ensure that any fluorescence
changes observed in the assay reaction were not due to fluores-
cence quenching, but due to the bona fide inhibition of fluores-
cent nucleotide binding.
Association and Dissociation Time Course—Fluorescence
measurements were made with a spectrofluorometer (Photon
Technology International). The excitation and emission wave-
lengths were 480 and 530 nm, respectively. BODIPY FL GTP
at 500 nM in aHEPES buffer (30mMHEPES, pH 7.2, 40mMKCl,
100mMNaCl, 0.1% (v/v)Nonidet P-40, 1mMDTT, 1mMEDTA
and 0.1% BSA) was first added to a 7  45-mm glass cuvette
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(Sienco) followed by an equal amount of buffer containing
either 400 nM enzyme or 400 nM enzymeplus 10Mcompound.
The fluorescence changes were immediately recorded. For the
dissociation kinetic studies, either compound at a final concen-
tration of 10 M or GTP at 250 M was added to the reaction.
The dissociation time course was fitted to a single exponential
equation (supplemental Equation 1) to obtain koff. The concen-
tration of GTP or CID2950007 did not affect the determination
of the dissociation rate constant.
Equilibrium Binding Assay—Wild-type GST-Cdc42 was
bound to GSH beads in NP-HPSE buffer (30 mM HEPES, pH
7.2, 40 mM KCl, 100 mM NaCl, 1 mM EDTA and 0.1% (v/v)
Nonidet P-40) overnight at 4 °C. The beads were washed twice
and resuspended with NP-HPSE buffer supplemented with
0.1% BSA and 1mMDTT. CID2950007 at a final concentration
of 10 M and increasing concentrations of BODIPY FL GTP
were added to the suspension. Samples were incubated at 4 °C
for 2.5 h, and binding of the fluorescent nucleotide to the
enzyme wasmeasured using the CyAnTMADP flow cytometer.
Raw data were exported, and the curves were fitted using the
one-site binding equation (supplemental Equation 2) from
GraphPad Prism 5.
Cytotoxicity Assays—Cells were cultured in growth medium
and tested using eitherMTSorCellTiter-Glo (Promega) assays.
ForOVCA429 and SKOV3ip, cells were plated in 12-well plates
at 1  104 cells/well and allowed to attach for 4 h. Then, fresh
mediumcontainingCID2950007 ranging from0.1 to 10Mwas
added to replace the old medium. The cells were allowed to
grow for 95 h before being treated with 600 M MTS reagents
and 25 M phenazine methosulfate for 2 h. Reactions were
stopped by the addition of 10% sodiumdodecyl sulfate. Absorb-
ance at 490 nmwas read using a SpectraMaxmicroplate reader
(Molecular Devices). For U937 ST, Swiss 3T3, and Vero E6
cells, the CellTiter-Glo luminescent cell viability assaywas con-
veniently conducted according to manufacturer’s protocol.
Briefly, cells were seeded in 96-well plates. Compounds were
tested at increasing concentrations (0.5–30 M) for 1–48 h in
accordance with the doses and times employed in the cellular
assays using these cell lines. After adding luciferase substrate,
the luminescence was read on a plate reader. Seeding cell den-
sities were confirmed to be in the linear range of the lumines-
cence change.
GLISA—Swiss 3T3 cells were continuously passaged at sub-
confluence and used to monitor the capacity of compounds to
block stimulus-mediated activation of Cdc42 or Rac1 in vivo.
Vero E6 cells are responsive to calpeptin-mediated stimulation
of RhoA and thus were used as a second cell line for assessing
compound effects on RhoA activity. Commercial GLISA kits
customized to capture activated Cdc42, Rac1, or RhoA from
cell lysates were used per manufacturer’s instructions (Cyto-
skeleton). Cells were serum-starved by sequentially removing
serum over a 3-day period and treated with either 0.1% DMSO
or 1 or 10 M compound for 60 min. Subsequently, samples
were treated with 100 ng/ml EGF for 2min to activate Cdc42 or
Rac1 or with 1 g/ml calpeptin for 30 min to activate RhoA.
DMSO-treated cells were left either unstimulated to determine
base-line GTPase activation or stimulated without drug treat-
ment to determine maximal GTPase activation. Cell lysates
were frozen, and active Cdc42 and Rac1 were quantified based
on a p21-activated protein kinase binding assay (27), whereas
active RhoA was quantified based on a rhotekin binding assay
(28). All assays were performed in 96-well microtiter plates.
Purified GTP-loaded Cdc42, Rac1, or RhoA control proteins
were included in each assay to quantify active GTPases in the
lysates.
RhoA activation was independently confirmed by monitor-
ing actin stress fiber formation following calpeptin stimulation
(1 g/ml) for 30 min. Actin filaments in control and stimulated
cells were detected following paraformaldehyde (4%) fixation
and Triton X-100 (0.5%) permeabilization using Alexa Fluor
488 phalloidin (1 unit, or 0.17 M) (Life Technologies).
Immunofluorescence Staining and Microscopy—Filopodia
formation was measured according to established protocols
(29). Briefly, Swiss 3T3 cells were grown on coverslips. Brady-
kinin at 100 ng/ml was added to stimulate cells for 10min. Cells
were washed with phosphate-buffered saline and fixed with 4%
paraformaldehyde followed by permeabilization for 5 min with
0.1% Triton X-100 in Tyrode’s buffer and blocking for 1 h with
1% BSA in Tyrode’s buffer. Cells were stained with rhodamine
phalloidin to label filamentous actin and then mounted in Pro-
Long Gold (Life Technologies). A Zeiss LSM510 META with
63 1.4NA objective was used to acquire the images at 1024
1024 pixels. To study the compound effect, cells were treated
with CID2950007 (10 M, from 10 mM stock in DMSO) or
DMSO (0.1%, v/v) for 1 h before the addition of bradykinin.
CID44216842 was similarly tested in one trial (10 M, from 10
mM stock in DMSO). Trends were similar to those shown for
CID2950007 without reaching statistical significance and
therefore are not shown. For each condition, 30–60 cells were
randomly chosen and imaged. Filopodia were defined as hair-
like protrusions, positive for actin 0.5–1 m in diameter. The
number and length of filopodia present on each cell weremeas-
ured using SlideBook software. SlideBook traces of filopodia
measured in pixels were converted to m based on 1 m  28
pixels for 63 image at 1024  1024 pixels. The experiment
was repeated three times.
Cell Migration Assay—OVCA429 and SKOV3ip cells were
plated at 1  104 cells/well in 24-well Boyden chambers and
allowed to attach for 4 h. Then, compounds at final concentra-
tions ranging from 0.1 to 10 M were added to the growth
media. After 48 h, inserts were removed and stainedwithDAPI.
Membrane filters were imaged on a Zeiss inverted microscope
using a 20 objective, and three representative fields were
counted from each treatment group.
Host-Virus Interaction Assay—For infection assays, Vero E6
cells were incubated with 10 M CID2950007 for 30–45 min
before being exposed to infectious Sin Nombre virions (multi-
plicity of infection 0.1) for 30 min in the presence of com-
pound. Control cells were treated with 0.1% DMSO in lieu of
compound. Following virus entry, unbound Sin Nombre viri-
ons were removed with low pH buffer treatment for 1 min and
washed three more times in PBS. The low pH buffer contained
40 mM sodium citrate, pH 3.0, 10 mM KCl, and 135 mM NaCl.
The cellswere then incubated inmediumeitherwith orwithout
the compound for 24 or 48 h. TaqMan RT-PCR was used to
measure viral S-segment 24–48 h after infection according to
A Cdc42 Inhibitor
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previously described procedures (30, 31). Briefly, viral RNAwas
extracted from cells using the RNeasy kit and reverse-tran-
scribed with SuperScript III (Life Technologies). The primer
was an S-segment-specific sense primer (5-agcacattacagagca-
gacgggc-3). The resultingDNAwas PCR-amplifiedwith S-seg-
ment-specific primers (5-gcagacgggcagctgtg-3 and 5-agat-
cagccagttcccgct-3) and a fluorescently labeled TaqMan probe
(5-FAM-tgcattggagaccaaactcggagaactt-TAMRA-3) in tripli-
cate reactions using Taq Gold. The fluorescence was measured
on an ABI Prism 7000 sequence detection system (Life Tech-
nologies). A standard curve drawn from S-segment template of
known copy numbers was used to quantify the viral RNA.
LDV Binding Assay—The procedure was based on an estab-
lished protocol withminor changes (25, 32). TheU937 FPRST
cell, which has desensitizing mutations toward N-formyl pep-
tide (33), was used to extend the signal observation window.
The cells were grown in RPMI 1640 supplemented with 2 mM
L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin,
and 10% heat-inactivated fetal bovine serum. For the binding
experiment, cells at 0.4–0.8  106 cells/ml were constantly
stirred with a magnetic stir bar, and the fluorescence was
recorded on a FACScan flow cytometer (Block Scientific).
LDV-FITC at a final concentration of 4 nM and N-formyl pep-
tide at 100 nMwere sequentially added followed by the addition
of either compound at different concentrations or an equal vol-
ume of DMSO. Nonfluorescent LDV was added at 1 M to
dissociate the remaining LDV-FITC. The inhibition percentage
was calculated according to supplemental Equation 3. The
experiment has been repeated at least three times.
Statistical Analyses—One-way ANOVAwith Dunnett’s post
test was conducted to compare differences between the means
of each group relative to the control group for cytotoxicity,
migration, GLISA, filopodia, virus infection, and integrin acti-
vation assays. Statistical significance was accepted at p  0.05
and denoted by an asterisk in the figures. GraphPad Prism was
used to perform statistical analyses.
RESULTS
CID2950007 and Its Analog Specifically Inhibit GTP Bind-
ing to Cdc42—Compound CID2950007 and its analog
CID44216842 were synthesized as described in the supplemen-
tal data. The effect of each compound on the binding of
BODIPY FL GTP to eight different GTPases was compara-
tively assessed in a multiplex assay (Fig. 1). The eight GTPases
FIGURE 1. Two structural analogs selectively inhibit Cdc42 nucleotide binding activity. A, structures of CID2950007 and its analog CID44216842. B, the
concentration effects of CID2950007 and CID44216842 on eight GTPases. The curves were fitted to the sigmoidal dose-response equation using GraphPad
Prism. The percentage of response was calculated as the ratio of (sample MCF  negative control MCF)/(positive control MCF  negative control MCF) (where
MCF is median channel fluorescence). For the positive control, DMSO instead of the compound was added; for the negative control, the compound was
replaced with GTP at a concentration 5000-fold greater than BODIPY FL GTP. The EC50 for Cdc42 wild type and Cdc42Q61L mutant were 2.1 and 2.6 M,
respectively, for CID2950007 and 1.0 and 1.2 M, respectively, for CID44216842. C, the concentration effects of the two compounds on BODIPY FL GDP binding
to eight GTPases. The EC50 values for Cdc42 wild type and Cdc42Q61L mutant were 1.4 and 2.9 M, respectively, for CID2950007 and 0.3 and 0.5 M,
respectively, for CID44216842. Data shown are representative of at least three independent sets of measurements with each set conducted in duplicate.
A Cdc42 Inhibitor
8534 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288 • NUMBER 12 • MARCH 22, 2013
 at U
niversity of K
ansas L
ibraries on A
pril 8, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
areH-Ras and itsG12Vconstitutively activemutant; Cdc42 and
its Q61L constitutively active mutant; Rac1 and its Q61L con-
stitutively active mutant; and RhoA and Rab7, which are repre-
sentativemembers of theRas, Rho, andRab subfamilyGTPases.
The compounds inhibited BODIPY FL GTP binding to both
Cdc42 and its mutant in a dose-dependent manner. The inhi-
bition was specific toward Cdc42 with no effects on other
GTPases including Rac and Rho in the same family (Fig. 1B).
CompoundCID44216842had a slightly improvedEC50 as com-
pared with CID2950007 for both Cdc42 and its mutant. How-
ever, biophysical characterization showed that the analog had
decreased solubility. Therefore, CID2950007 remained the pri-
mary focus of subsequent characterizations. The fluorescence
decrease was confirmed to be due to bona fide inhibition of
BODIPY FL GTP binding and not a result of fluorescence
quenching (see ”Experimental Procedures,“ data not shown).
The nucleotide identity appears not to be essential for the inhi-
bition by CID2950007 because the compound also selectively
inhibited BODIPY FL GDP binding to Cdc42 and its mutant
(Fig. 1C). The concentration of the fluorescent guanine nucle-
otide in the assay was fixed close to its Kd. According to the
Cheng-Prusoff equation (34), the EC50 obtained under our
assay condition is a close estimate of the Ki of the compound.
Residual fluorescent GTP binding was observed even at high
compound concentrations. Remaining activity may suggest the
presence of multiple conformers of the commercially obtained
Cdc42 protein and its mutant. To the best of our knowledge,
CID2950007 and its analog are the first small molecules that
show specific inhibition of nucleotide binding toward Cdc42
GTPase.
CID2950007 Is a Noncompetitive Inhibitor—To examine the
mechanism of CID2950007 inhibition, its effects on the equi-
librium binding and the binding and dissociation kinetics of
BODIPY-labeled guanine nucleotide were assessed. The fluo-
rescence of BODIPY-labeled guanine nucleotide will increase
when bound to GTPases due to release of steric hindrance (35,
36). The change can be captured in real time on a fluorometer.
First, the nucleotide content of the enzymes used was quanti-
fied, and it was found that the GST-tagged enzymes were
mostly apo-proteins (supplemental data). Then, the inhibition
mechanism was studied in a kinetic dissociation assay. When
Cdc42 was added to a solution of BODIPY FL GTP, there was
a fluorescence increase indicating the binding of the nucleotide
to the protein. After equilibrium was reached, either GTP or
CID2950007 was added. The dissociation of BODIPY-labeled
nucleotide was observed, but with different kinetics in the two
cases (Fig. 2A). When the time course was fitted to a single
exponential equation, the calculated dissociation rate constants
were 0.008 and 0.002 s1, respectively. Therefore, GTP and
CID2950007 induced the dissociation of BODIPY-labeled
guanine nucleotide through different mechanisms. Although
GTP directly competed with the fluorescent nucleotide by
binding to the active site of Cdc42, CID2950007 likely provoked
the dissociation by binding to a location other than the active
site. In the subsequent equilibriumbinding assay, the binding of
BODIPY FL GTP to Cdc42 was measured in the presence or
absence of 10 M CID2950007 (Fig. 2B). The binding curves
were fitted to a hyperbolic one-site binding equation (supple-
mental Equation 2). Both the maximum fluorescence (Bmax),
which is indicative of themaximumguanine nucleotide binding
that can be achieved, and the apparent dissociation constantKd
changed (Fig. 2B). A competitive inhibitor will be outcompeted
by BODIPY FL GTP of high concentrations. Therefore, the
Bmax will remain the same in the presence of a competitive
inhibitor. The observed significant change on Bmax suggests a
noncompetitive mechanism of action from CID2950007.
Moreover, in the kinetic binding studies, before being added to
the solution of BODIPYFLGTP, the enzymeCdc42was either
not treated or added with compound CID2950007 (Fig. 2C). If
the compound can bind to Cdc42 as a fast binding competitive
inhibitor (34), we should expect to see BODIPY FL GTP bind
to the inhibited Cdc42 at a different rate as compared with
binding to the uninhibited Cdc42. Also, the fluorescent level
that could be achieved from BODIPY FL GTP binding should
be much lower. These expectations were contrary to observa-
tion. In the presence of the inhibitor, BODIPY FL GTP bound
to Cdc42 at a rate comparable with that in the absence of the
inhibitor and achieved a comparable fluorescence level, arguing
against a competitive mechanism. A fluorescence decrease,
which is a reflection of BODIPY FL GTP departure, was only
observed after a significant fluorescence increase, suggesting
that CID2950007 binds to an allosteric site of Cdc42 only after
the enzyme has been loaded with BODIPY FL GTP at the
active site and then induces the dissociation of the nucleotide.
An analogous binding curve was observed when CID2950007
was replaced with its analog CID44216842, confirming the lack
of artifacts associated with CID2950007 (Fig. 2D, blue curve).
EDTA in the buffer facilitated nucleotide binding and associa-
tion and allowed the kinetics to be studied in a tractable time
frame.Without EDTA, CID2950007 still induced BODIPY FL
GTP dissociation from Cdc42, although at a slower rate (Fig.
2E). In these kinetic studies, the hydrolysis of BODIPY FL
GTP was not resolved, possibly due to the low intrinsic hydrol-
ysis activity of GTPases (37). However, it was found that the
identity of the guanine nucleotide was not important.
CID2950007 similarly induced the dissociation of BODIPY FL
GDP (Fig. 2F) where hydrolysis was not an issue. This observa-
tion corroborates the result that CID2950007 inhibited
BODIPY FL GDP binding in a dose-dependent manner with
comparable EC50 values (Fig. 1). Finally, the effect of
CID2950007 is specific toward Cdc42 with no activity toward
Ras and Rac1 (Fig. 2, G and H). Together, these findings are
consistent with the notion that CID2950007 is a selective non-
competitive andmost likely conformation-dependent allosteric
inhibitor that binds to guanine nucleotide-bound Cdc42,
induces the dissociation of the ligand, and locks the protein in
an inactive conformation (Fig. 2I).
Cell-based Analyses of CID2950007 Demonstrate in Vivo
Utility for Identifying and Characterizing Cdc42-dependent
Processes—Cdc42 is important for actin remodeling, endocyto-
sis, cell adhesion, and migration. Therefore, the identified
Cdc42 inhibitor was tested in a variety of cell-based assays to
demonstrate utility for cellular analyses of Cdc42 functions.
Processes well known to depend onCdc42 (filopodia formation
and cell migration) were used first to establish cellular activity,
and subsequently, the effect of the inhibitor was tested in situ-
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ations where Cdc42 activity was implicated (hantavirus entry
and integrin activation), but not yet directly demonstrated.
Assessment of Cytotoxicity—The cytotoxicity of compounds
CID2950007 and CID44216842 was assessed in cells including
neutrophils, fibroblasts, kidney epithelia, and ovarian cancer
lines based on either formazan dye or luminescence assays.
OVCA429 and SKOV3ip cell lines are both from human ovary
carcinomas where Cdc42 is activated by upstream signal trans-
ducers (15–17). CID2950007 was not cytotoxic in either cell
line at doses of 0.1–3Mafter treatment for 4 days (Fig. 3,A and
B). OVCA429 cells were insensitive to 10 M compound,
whereas some cytotoxicity was observed in SKOV3ip cells at
this concentration after a 4-day treatment, although it did not
reach statistical significance. CID2950007 was not cytotoxic
A Cdc42 Inhibitor
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toward Swiss 3T3 or Vero E6 cells up to 10 M for 24 and 48 h,
respectively (Fig. 3, C and D). Neither CID2950007 nor
CID44216842 was cytotoxic toward U937ST cells at concen-
trations up to 10 M for 24 h and up to 30 M after 1 h (Fig. 3,
E–H). All subsequent cell-based assays were performed using
CID2950007 or CID44216842 at concentrations and incuba-
tion times where no cytotoxicity was evident.
CID2950007 and CID44216842 Inhibit Stimulus-induced
Cdc42 Activation, but Not Rac1 and RhoA—Effector protein
binding assays (GLISA) were used to assess the ability of the
compounds to inhibit Cdc42 activation in cells and monitor its
selectivity relative to other Rho family members. Swiss 3T3
fibroblasts were treated with each of the compounds and then
subjected to EGF stimulations to activate Cdc42 and Rac1.
Compound effects on RhoA activation were measured in Vero
E6 kidney epithelia cells after calpeptin stimulation. Both com-
pounds significantly inhibited Cdc42 activation at 10 M,
whereas neither compound inhibited Rac1 or RhoA activation
at the same concentration (Fig. 4, A–C). The GLISA data are
consistent with in vitro blockade of the interaction between
Cdc42 and p21-activated protein kinase measured using a bio-
chemical pull-down assay (21). Thus, the compounds exhibit
Cdc42 selectivity in cell-based assays and can be used to assess
Cdc42 dependence of cellular pathways and processes.
CID2950007 Inhibits 3T3 Fibroblast Filopodia Formation—
Filopodia are Cdc42-induced cytoplasmic projections contain-
ing bundled actin filaments with functions in cell adhesion,
migration, and invasion (29, 38). Filopodia formation is
enhanced by chemotropic cues, enabling cell migration along a
directed path. As expected, stimulation of 3T3 fibroblasts by
bradykinin treatment increased both the numbers and the
length of filopodia formed on the expanding edge relative to
resting control cells (Fig. 5A). However, when the cells were
incubated with 10 M CID2950007 for 1 h prior to bradykinin
treatment, both the number and the average length of filopodia
were decreased (Fig. 5,B andC). DMSO (0.1%, v/v) treatment as
a control had no effect on filopodia formation relative to bra-
dykinin stimulation, but did increase filopodia length similar
to bradykinin, most likely due to the cell ruffling effect of
DMSO that has been previously reported (39, 40). Because
CID2950007 must be dissolved in DMSO and diluted into
aqueous solution, the inhibitory effect of the compound is dem-
onstrated by its ability to counteract the stimulatory effects of
both DMSO and the bradykinin cue. Together, the data dem-
onstrate that CID2950007 is a potent inhibitor of filopodia for-
mation, a process that is well known to be directly regulated by
Cdc42.
CID2950007 Inhibits Ovarian Cancer Cell Migration—
Cdc42-induced filopodia are important to themobility ofmany
cell types (41, 42). Down-regulation of Cdc42 through genetic
methods reduces the ability of cells to manage directed migra-
tion in a chemokine gradient (43). Ovarian cancer is character-
istically metastatic, and Cdc42, which is activated by p70 S6
kinase in ovarian cancer, has been speculated to be accountable
for the migratory phenotype (16). In a Boyden chamber assay,
CID2950007 clearly inhibited the migration of human ovarian
carcinoma cell lines OVCA429 and SKOV3ip in a dose-depen-
dent manner (Fig. 6, A and B). At 3 M, the compound reduced
cell migration to less than 50% of the untreated control. Impor-
tantly, there was no cytotoxicity for either OVCA429 or
SKOV3ip at this concentration (Fig. 3, A and B). In addition, a
commercially available Rac inhibitor NSC23766 also com-
pletely inhibited OVCA429 migration at 10 M (data not
shown). Cdc42 andRac1 are known to be involved in cellmigra-
tion through distinct pathways (44, 45). However, the coordi-
nate function and the relative importance of each pathway have
been incompletely assessed, and previous studies have largely
relied on mutant GTPase overexpression. The fact that inhibi-
tion of either GTPase alone with small molecule inhibitors
could restrain migration indicates an important interplay
between Rac- and Cdc42-regulated pathways in ovarian cancer
cell migration.
CID2950007 Inhibits Cdc42-regulated Virus Infection—Due
to its roles in actin cytoskeleton organization and vesicle traf-
ficking, Cdc42 is frequently involved in the pathogen internal-
ization during viral infections (8). Cdc42 may regulate the for-
mation of macropinosomes; however, its exact roles in viral
infection are not well understood. Previous studies have largely
depended on the use of Cdc42-activating and -inactivating
mutants or broad spectrum Rho inhibitors such as C. difficile
toxin B (46–48). Only recently has secramine been used to
inhibit the cell-to-cell spread of HIV (49). Sin Nombre virus
causes hemorrhagic fever that is associated with significant
mortality and morbidity. The mechanistic details regarding its
uptake are unknown. To test the potential role played by Cdc42
and its effectors, host cells were incubated with CID2950007
and infected with Sin Nombre virus. The amount of the viral
RNA was quantified 24–48 h later. CID2950007 treatment
only during the initial virus exposure gives an estimation of
Cdc42 requirement for virus entry, whereas compound treat-
ment for 24–48 h demonstrates nearly complete inhibition of
viral replication (Fig. 7). Therefore, the use of CID2950007
establishes for the first time a role for Cdc42 in Sin Nombre
virus internalization. The results further suggest that the inhi-
FIGURE 2. CID2950007 is an allosteric inhibitor of Cdc42. A, compound CID2950007 and GTP induce the dissociation of BODIPY FL GTP through different
mechanisms. After BODIPY FL GTP bound to Cdc42, either 250 M GTP (red) or 10 M CID2950007 (purple) was added. The fluorescence curves were fitted to
a single exponential equation to get dissociation rate constants (supplemental Equation 1). The concentration of GTP or CID2950007 did not affect the
determination of the dissociation rate constant. B, the presence of CID2950007 changed both Bmax and Kd in the BODIPY FL GTP equilibrium binding assay. C,
CID2950007 inhibited BODIPY FL GTP binding. An equal amount of buffer (green), 400 nM Cdc42 (red), 400 nM Cdc42  0.1% DMSO (blue), or 400 nM Cdc42 
10 M CID2950007 (purple) was added to a solution of 500 nM BODIPY FL GTP. The inset shows the expanded view of the initial fluorescence change. D, analog
CID44216842 has similar effects as CID 2950007 toward BODIPY FL GTP binding to Cdc42. E, buffer was the same as that in A except that without EDTA,
CID2950007 inhibited BODIPY FL GTP binding at a slower rate. The inset shows the expanded view of the initial fluorescence change. F, CID2950007 inhibits
BODIPY-GDP binding to Cdc42 similar to BODIPY-GTP binding. G and H, CID2950007 did not inhibit BODIPY FL GTP binding to Ras (G) or Rac1 (H). Fluorescence
intensity was normalized as percentage using the equilibrium reading as the maximum against which the percentage was obtained. Conditions were the same
as that in A. I, model of the CID2950007 inhibition mechanism. After guanine nucleotide binds to Cdc42, CID2950007 associates with the complex and induces
the dissociation of the guanine nucleotide. The resulting Cdc42 complex is locked in an inactive conformation. Experiments were performed in at least
duplicates. Representative curves are shown.
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bition of Cdc42 by CID2950007 will be useful for more broadly
testing the requirement for Cdc42 in the entry of other viruses.
CID2950007 Inhibits LDV Binding to VLA-4 Integrin—Very
late antigen-4 (VLA-4) is an integrin commonly expressed on
the leukocyte plasma membrane. At the site of injury, the che-
motactic agent released by the infecting object stimulates the
conformational change of VLA-4, which can then bind with
high affinity to the integrin receptor vascular cell adhesionmol-
ecule-1 (VCAM-1) that is expressed on the endothelium. The
arrest of the leukocyte subsequently initiates a cascade of
immune responses. Strong evidence supports the involvement
of Rho and Rac GTPases in the signaling pathway that is acti-
vated by chemotactic ligands and leads to integrin conforma-
tional change (50–52). Whether Cdc42, which is in the same
GTPase family, also plays a role has not been previously clari-
fied. A real-time flow cytometry-based assay was used to dem-
onstrate the usefulness of CID2950007 in this cellular context.
A fluorescently labeled LDV peptide, LDV-FITC, was used in
which the LDV peptide constitutes the fragment of VCAM-1
that interactswithVLA-4. The activation status ofVLA-4 could
be monitored by the fluorescence associated with the VLA-4-
expressing U937 cells. The cells initially bound LDV-FITC at
the basal level. After fMLFF stimulation, VLA-4 changed to a
high affinity state, which was accompanied by increased LDV-
FITC binding. The fluorescence level of the cells was therefore
increased. The addition of CID2950007 and its analog caused a
dose-dependent loss of fluorescence due to reduced VLA-4
affinity and LDV dissociation, whereas the same amount of
DMSO had no effect (Fig. 8). The inhibition is faster than that
observed in the biochemical kinetic binding assay, possibly
FIGURE 3. CID2950007 did not show cytotoxicity in multiple cell lines. A
and B, cell viability measured toward OVCA429 (A) and SKOV3ip (B) cells after
a 4-day incubation at 0.1–10 M using MTS assay. C–H, cell viability measured
using luminescence assay. C, compound CID2950007 tested on Swiss 3T3
cells at concentrations of 0.5–10 M for 24 h. D, compound CID2950007
tested on Vero E6 cells at concentrations of 0.5–10 M for 48 h. E and F, com-
pound CID2950007 tested on U937 ST cells up to 10 M for 24 h (E) and up to
30 M for 1 h (F). G and H, compound CID44216842 tested on U937 ST cells
up to 10 M for 24 h (G) and up to 30 M for 1 h (H). A and B represent three
independent trials with assays conducted in duplicate or triplicate. From C–H,
experiments were conducted in at least triplicate. Means 	 S.E. from all trials
are plotted. For compound treatments at the experimental concentrations
and time durations, there were no differences with p  0.05 based on one-
way ANOVA with Dunnett’s post test and relative to either untreated control
cells (A and B) or DMSO-treated cells (C–H). Statistical significance assessment
was the same using either as the comparison group. RLU, relative light units.
FIGURE 4. Cdc42 activation was specifically inhibited by CID2950007 and
its analog CID44216842 as demonstrated by the GLISA assay. A and B,
Swiss 3T3 cells were serum-starved and then pretreated with compounds
CID2950007 or CID44216842 at indicated concentrations as detailed under
”Experimental Procedures.“ Cells were subsequently stimulated with EGF to
activate Cdc42 or Rac1 and compared with unstimulated cells. Control cells
were mock-treated with 0.1% DMSO to account for compound diluent. After
cell lysis, the amounts of active Cdc42 or Rac1 were quantified based on
p21-activated protein kinase binding by GLISA. The following conditions
were used: Cdc42, nine independent trials for CID2950007 and two inde-
pendent trials for CID44216842 with duplicate or triplicate samples for each
condition; Rac1, three independent trials for CID2950007 with duplicate or
triplicate samples and one trial for CID44216842 with triplicate samples. C,
Vero E6 cells were serum-starved, treated with CID2950007 or CID44216842,
and stimulated with calpeptin to activate RhoA with one trial in triplicate.
Immunofluorescence micrograph confirms RhoA activated stress fiber forma-
tion. Purified GTP-loaded Cdc42, Rac1, or RhoA control proteins were used to
calculate the ng of activated GTPase. Means 	 S.E. with EGF control sub-
tracted from all trials are plotted. Asterisks denote p  0.05 based on one-way
ANOVA with Dunnett’s post test and relative to EGF- or calpeptin-stimulated
control cells.
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due to the effects of multiple intracellular regulators that
facilitate the nucleotide association and hydrolysis. Because
CID2950007 is a Cdc42-selective inhibitor, our observation
suggests the involvement of Cdc42 in the integrin VLA-4 sig-
naling pathway. In addition, this analysis also allowed a real-
time evaluation of the rate at which CID2950007 entered the
cells and exerted its inhibitory effect.
DISCUSSION
The pursuit of GTPase inhibitors has been an enduring effort
due to the important roles that this class of proteins plays in cell
physiology and the strong indications they have in cancers,
immune diseases, and neurological disorders (53–56). Spe-
cifically, Cdc42 has been implicated in ovarian cancer (16),
breast cancer (57), hepatitis C virus-related liver disease
(58), and mental retardation (59). However, there has been
limited success in GTPase inhibitor discovery. Prior Cdc42
inhibitors either lack selectivity by acting on multiple
GTPases or only target particular protein-protein interac-
tions (19, 60). The function of Cdc42 is controlled by multi-
ple upstream regulators and downstream effectors (41).
Blocking one set of interactions may be useful in some sce-
FIGURE 5. CID2950007 decreased filopodia formation in 3T3 cells after bradykinin treatment. A, representative images of resting control cells, cells
stimulated with 100 ng/ml bradykinin, and cells incubated with 10 M CID2950007 for 1 h before the addition of bradykinin. Cells were permeabilized and
stained as described under ”Experimental Procedures“ before the pictures were taken on a Zeiss LSM 510 Meta. Lower panels show 6.5-fold magnified views of
boxed areas in top panels. The blue line shows tracing of filopodia for quantification. B, numbers of filopodia per cell. C, length of filopodia on each cell, 1 m 
28.5 pixels. The experiment was repeated three times, and 30 – 60 cells were randomly imaged and analyzed. Mean lengths or number of filopodia 	 S.E. from
a single experiment are plotted. Asterisks denote p  0.05 based on one-way ANOVA with Dunnett’s post test relative to bradykinin-stimulated control cells.
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narios. However, the protein could still remain active by
interacting with other partners and allow undesirable
bypasses. Moreover, sequestering a shared GDI would
affect the function of other GTPases. We report here the
characterization of a selective small molecule inhibitor for
Cdc42 and a second active analog. Numerous other structur-
ally related analogs were tested and found inactive
(supplemental Fig. S1), confirming specificity. The com-
pounds inhibit Cdc42 while sparing Rac and Rho that are in
the same GTPase family and have high sequence and struc-
ture homology to Cdc42. Furthermore, using a real-time flu-
orescence assay, CID2950007 was shown to be an allosteric
inhibitor that binds the guanine nucleotide-associated
Cdc42 and induces ligand dissociation. Supplemental Fig. S2
shows predicted docking of the compounds. In collaboration
with Dr. Roger Goody (Max-Planck Institute of Physical
Chemistry, Dortmund, Germany), crystallization trials were
conducted and led to the conclusion that the synthesis of
derivatives that can be covalently cross-linked to the GTPase
will be required. It also remains to be determined how the
compound affects RhoV, RhoU, and RhoJ GTPases that are
often expressed in a cell type-specific manner and are clas-
sified as Cdc42-like GTPases (61, 62).
BODIPY FL GTP has been widely used in research with
guanine nucleotide-binding proteins because of its high sensi-
tivity and the minimal interference from the fluorescent label
(63). As compared with radioisotope-labeled nucleotide ana-
logs, it is environmentally friendly and convenient to use. The
fact that CID2950007 was discovered in a fluorescence-based
screening campaign using BODIPY FL GTP (21) and in the
present study validated in multiple biochemical and cellular
assays again proved the effectiveness of BODIPY-labeled gua-
nine nucleotide in GTPase studies.
Many currently available GTPase inhibitors target protein-
protein interaction interfaces. Dbs is a GEF for both Cdc42
and RhoA. Whether CID2950007 can affect Dbs-facilitated
guanine nucleotide exchange on Cdc42 was tested with min-
imal effect detected (supplemental Fig. S3). Because the
compound can displace both GDP and GTP and is inhibitory
in cell-based assays, the compound could act independent of
any effect on GEF activity or interaction, as supported by the
docking studies (supplemental Fig. S2). In this model, con-
sistent with the proposed allosteric mechanism, the com-
pound is found to bind to an allosteric pocket adjacent to the
nucleotide binding site to promote nucleotide dissociation
and thus would not interfere with GEF binding to the switch
regions (supplemental Fig. S2). However, small molecules
may block a selective subset of protein-protein interactions
as exemplified by NSC23766, which blocks Rac1 interaction
with the Tiam and Trio GEFs, but not with Vav (64). There-
FIGURE 6. CID2950007 inhibited the migration of OVCA429 (A) and
SKOV3ip (B) cells in a dose-dependent manner. Cells were allowed to
attach to the Boyden chambers. CID2950007 at indicated concentrations
were added to the growth media. Membrane filters were imaged 48 h later.
All assays represent three independent trials with three representative fields
counted for each treatment. Means 	 S.E. from all trials are plotted. Asterisks
denote p  0.05 based on one-way ANOVA with Dunnett’s post test and
relative to migration of untreated control cells. Statistical significance was the
same when treated samples were compared with 0.1% DMSO treatment
group.
FIGURE 7. CID2950007 inhibited Sin Nombre virus infection efficiency.
CID2950007 at 10 M was added to host Vero E6 cells either only during
virus contact (60 –75 min) followed by reincubation for 24 – 48 h in the
absence of the compound or during virus contact and maintained
throughout the culturing period after viral contact (24 – 48 h). The two
conditions provide an indication of CID2950007 effects on virus entry
alone as compared with effects on virus entry and replication. Viral RNA
content was quantified after 24 or 48 h as described under ”Experimental
Procedures.“ Viral infection experiments were repeated three times with
3– 6 replicates per trial. Means 	 S.E. from all trials are plotted. Asterisks
denote p  0.05 based on one-way ANOVA with Dunnett’s post test and
relative to infected control cells without compound treatment at the rel-
evant time point. SNV, Sin Nombre virions.
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fore, it is still too early to conclude whether CID2950007
could affect the interaction between Cdc42 and its other
specific GEFs besides being able to block the guanine nucle-
otide binding to the GTPase.
Previously, the function of Cdc42 in mammalian cells has
been studied using its dominant-negative or constitutively
active mutants (65–67). However, these mutants can impede
the functions of other GTPases with which Cdc42 shares
upstream regulators and downstream effectors. For instance, a
dominant-negative mutant can bind a shared GEF, whereas a
constitutively active mutant may occupy a mutual effector,
making them unavailable to other GTPases. Therefore, such an
approach imposes limitations related to specificity, dosage, and
clonal variability (68). The use of a small molecule-selective
inhibitor instead achieves selective inactivation of Cdc42
within a short time window and leaves analogous GTPases
unaffected. This should greatly facilitate the functional assign-
ment of Cdc42 and help to disentangle complex GTPase
networks.
Due to its important roles in cytoskeleton organization, the
activity of Cdc42 could be assessed in filopodia formation
and cell migration assays. We observed that CID2950007
effectively inhibited Cdc42 in both assays, leading to less
filopodia formation and ineffective cell migration. Contrary
to our observation that Cdc42 promoted chemotaxis, which
was inhibited by CID2950007, some early studies reported
that Cdc42 negatively regulated cell migration (69). This
might be because the function of Cdc42 is cell type-specific
(42), or is likely due to the use of constitutively active Cdc42
mutants in those studies that may induce nonspecific effects
and bias the conclusions. This again shows the value of small
molecule-selective inhibitors.
Rac and Rho have been shown to be involved in the inside-
out signaling pathways triggered by chemokines. The signal-
ing results in 41-dependent up-regulation of the adhesion
capacity of T-lymphocytes and leukocytes (50–52). The
involvement of Cdc42 in the same GTPase family remains
unknown. In this study, the use of the small molecule Cdc42-
selective inhibitor strongly suggests the participation of
Cdc42. The briefness of the decrease of the fluorescence
level, which is an indication of the VLA-4 activation state,
indicates that redundant signaling pathways are capable of
compensating the inhibited Cdc42 (70). Moreover, our assay
represents a breakthrough in the methodology to study the
involvement of GTPases in integrin activation. Previous
studies typically used either immunoprecipitation or radio-
active labeling to isolate GTPases from the cell lysate and
quantify nucleotide incorporation (50–52). Such efforts are
often time-consuming and involve complicated waste dis-
posal. In addition, they would not reveal the concurrent
changes happening in the cells. On the other hand, our assay
could conveniently monitor the adhesion changes of the
cells in real time by using flow cytometry and fluorescently
labeled peptide.
In conclusion, we characterized a small molecule allosteric
inhibitor that selectively inhibits nucleotide binding to the
Cdc42 GTPase. The compound may find its applications in
drug development aimed at Cdc42-related diseases. As illus-
FIGURE 8. CID2950007 inhibited VLA-4 activation in a dose-dependent
manner. A, VLA-4 activation status is monitored in real time. LDV-FITC was
first added to U937 FPRST cells to achieve resting state binding (Kd 12 nM)
(25). Then, N-formyl peptide (N-fMLFF) was added to stimulate VLA-4 activa-
tion. When the ligand binding reached equilibrium, CID2950007 at the indi-
cated concentrations or an equal volume of DMSO was added. Nonfluores-
cent LDV was added to dissociate remaining LDV-FITC. B, quantification of the
CID2950007 inhibition effects. The inhibition percentage was calculated
according to supplemental Equation 3. At least three independent trials were
performed with each trial in duplicate. C, representative curves from one trial
are shown. B and D, means 	 S.E. from one trial are plotted. Asterisks denote
p  0.05 based on one-way ANOVA with Dunnett’s post test and relative to
DMSO treatment.
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trated by the examples, the compound can also help to unravel
the complex signaling pathways that often involve multiple
GTPases.
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PAGE 8534:
The revised Fig. 1A correctly shows CID44216842 as a 3-methoxy-
phenyl analog and not a 4-methoxyphenyl analog as originally pub-
lished. The correction does not impact the interpretations or conclu-
sions of the article.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 10, p. 6837, March 7, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
MARCH 7, 2014 • VOLUME 289 • NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 6837
ADDITIONS AND CORRECTIONS
Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of
these corrections as prominently as they carried the original abstracts.
